{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02010203",
      "OrgStudyIdInfo": {
        "OrgStudyId": "HS410-101"
      },
      "Organization": {
        "OrgFullName": "Heat Biologics",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT",
      "OfficialTitle": "Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response & Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2020",
      "OverallStatus": "Terminated",
      "WhyStopped": "Inability to accrue due to changing treatment landscape (PD-1 approvals)",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2017",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 5, 2013",
      "StudyFirstSubmitQCDate": "December 9, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 12, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "ResultsFirstSubmitDate": "July 31, 2019",
      "ResultsFirstSubmitQCDate": "February 13, 2020",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "February 17, 2020",
        "ResultsFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "February 13, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 17, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Heat Biologics",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Phase I/II study: Phase 1 is an open-label, safety study, patients who previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10^6 cells) HS-410 monotherapy. Phase 2, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10^6 cells) or high dose (1*10^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. Patients who do not receive BCG will be enrolled into an open-label, non-randomized group receiving high dose (1*10^7 cells) intradermal HS-410 monotherapy.",
      "DetailedDescription": "This study is a two part study: Phase I and Phase II. The Phase 1 portion is an open-label, safety study. Patients will have previously received 3-6 instillations of weekly intravesical Bacillus Calmette-Guerin (BCG) induction therapy (as standard of care) followed by low dose intradermal (1*10^6 cells) HS-410 monotherapy. In Phase 2, patients will be assigned to treatment groups based on whether they will receive induction BCG in the typical post-TURBT window. If the investigator plans to administer BCG, patients will be randomized to one of three blinded (physician-patient), placebo-controlled groups and receive either intradermal placebo or low dose (1*10^6 cells) or high dose (1*10^7 cells) vesigenurtacel-L in combination with induction and maintenance intravesical BCG. If patients will not receive BCG, they will be enrolled into an open-label, non-randomized group and receive high dose (1*10^7 cells) intradermal HS-410 monotherapy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Bladder Cancer"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "TURBT",
          "Bladder",
          "Cancer",
          "GP96",
          "Vaccine",
          "Immunotherapy",
          "Heat Biologics",
          "BCG",
          "Bacillus Calmette-Guerin",
          "Bacillus Calmette-Gu√©rin"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "104",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Phase I: HS-410 Low Dose",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: HS-410"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase II: HS-410 Low-Dose Plus BCG",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: HS-410",
                "Biological: BCG"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase II: High-Dose HS-410 Plus BCG",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: HS-410",
                "Biological: BCG"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase II: Placebo Plus BCG",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Placebo",
                "Biological: BCG"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase II: High-Dose HS-410",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: HS-410"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "HS-410",
            "InterventionDescription": "Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase I: HS-410 Low Dose",
                "Phase II: HS-410 Low-Dose Plus BCG",
                "Phase II: High-Dose HS-410",
                "Phase II: High-Dose HS-410 Plus BCG"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Placebo",
            "InterventionDescription": "Injection containing sterile solution but no cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase II: Placebo Plus BCG"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "BCG",
            "InterventionDescription": "Vaccine derived from a live bacterium",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase II: HS-410 Low-Dose Plus BCG",
                "Phase II: High-Dose HS-410 Plus BCG",
                "Phase II: Placebo Plus BCG"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Bacillus Calmette-Guerin"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Phase 1: Safety and Tolerability",
            "PrimaryOutcomeDescription": "To evaluate the safety and tolerability of vesigenurtacel-L",
            "PrimaryOutcomeTimeFrame": "Up to 3 years."
          },
          {
            "PrimaryOutcomeMeasure": "Phase 2: 1-year Disease-Free Survival",
            "PrimaryOutcomeDescription": "Arm 1, 2, 3: 1-year DFS in patients with NMIBC treated with BCG in combination with blinded study product (one of two doses of vesigenurtacel-L or placebo) Arm 4: 1-year DFS in patients with NMIBC treat1fv 9 with high dose vesigenurtacel-L monotherapy\n\nOne-year disease-free survival will be defined as the proportion of patients who are free from recurrent disease, progressive disease, and alive one year after the date of randomization/treatment assignment",
            "PrimaryOutcomeTimeFrame": "One year"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months",
            "SecondaryOutcomeDescription": "Evaluate the proportion of patients with recurrence at 3, 6, 12, 18, and 24 months",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months",
            "SecondaryOutcomeDescription": "Evaluate the proportion of patients with progressive disease at 3, 6, 12, 18, and 24",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Disease-free Survival at 3, 6, 18, and 24 Months",
            "SecondaryOutcomeDescription": "Evaluate Disease Free Survival at 3, 6, 18 and 24 months",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Overall Disease-free Survival",
            "SecondaryOutcomeDescription": "Evaluate overall Disease Free Survival",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Overall Survival, Expressed as the Number of Participants Alive",
            "SecondaryOutcomeDescription": "Evaluate overall survival (OS)",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Proportion of Patients Undergoing Cystectomy by 12 and 24 Months",
            "SecondaryOutcomeDescription": "Evaluate the proportion of patients undergoing cystectomy by 12 and 24 months from randomization",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Immunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.",
            "SecondaryOutcomeDescription": "Evaluate the proportion of patients with immunologic response of peripheral blood mononuclear cells (PBMCs) via intracellular cytokine staining (ICS) by flow cytometry and/or ELISPOT on CD8+ cells following vesigenurtacel-L vaccination",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Immunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated",
            "SecondaryOutcomeDescription": "Evaluate immunologic response of PBMCs (analysis of surface markers, CD3, CD4, CD8, CD19, CD25, CD45, CD56, FoxP3, and degranulation) and stimulation analysis via ICS of interferon gamma (IFNŒ≥) and granzyme B (gzB)",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Total PBMC Counts by Flow Cytometry",
            "SecondaryOutcomeDescription": "Evaluate total PBMC counts by flow cytometry, including lymphocyte subsets (B cells, helper T-cells, cytotoxic T-cells, natural killer (NK) cells and T-reg)",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Tumor Antigen Expression",
            "SecondaryOutcomeDescription": "Evaluation of pre-treatment tumor tissue for antigen expression",
            "SecondaryOutcomeTimeFrame": "At screening"
          },
          {
            "SecondaryOutcomeMeasure": "Tumor Infiltrating Lymphocytes (TILs)",
            "SecondaryOutcomeDescription": "Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "T Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment",
            "SecondaryOutcomeDescription": "Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs, T cell receptor sequencing of peripheral blood T cells before and during the course of treatment.",
            "SecondaryOutcomeTimeFrame": "Up to 2 years"
          },
          {
            "SecondaryOutcomeMeasure": "Safety of the Combination of the HS-410 and BCG",
            "SecondaryOutcomeDescription": "Phase 2 only Evaluate the safety of the combination of vesigenurtacel-L and BCG",
            "SecondaryOutcomeTimeFrame": "Up to 1 year"
          },
          {
            "SecondaryOutcomeMeasure": "Safety of the High Dose HS-410 Monotherapy",
            "SecondaryOutcomeDescription": "Phase 2 only Evaluate the safety of high dose vesigenurtacel-L monotherapy",
            "SecondaryOutcomeTimeFrame": "Up to 3 years."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nHistologically or cytologically confirmed non-muscle invasive bladder cancer [Ta, T1 or Tis (CIS)] that has been removed by transurethral resection\nEither: (i) high-risk disease, defined as T1 and/or high-grade and/or CIS or (ii) intermediate-risk disease, defined as Ta low-grade with at least 3 of the following 4 risk factors: multiple tumors, tumor size > 3cm, early recurrence (<1 year from previous staging procedure), or recurrence with a frequency of more than once in any 12 month period\nNot have received bacillus Calmette-Gu√©rin (BCG) or have completed previous BCG treatment > 12 months prior to the baseline staging procedure.\nPhase 2 Arms 1-3: Suitable to receive a 6-week course of BCG in the adjuvant setting within 6 weeks following TURBT. Phase 2 Arm 4: Suitable for monotherapy vaccine administration post-TURBT. For Phase 1 only: Has previously received 3-6 weekly doses of BCG.\nAdequate laboratory parameters\n\nExclusion Criteria:\n\nHuman immunodeficiency virus (HIV) infection or immunodeficiency disorders, either primary or acquired\nInfections or intercurrent illness requiring active therapy\nAny condition requiring active steroid or other immunosuppressive therapy\nActive malignancies within the past 12 months except negligible risk of metastasis or death treated with expected curative outcome.\nProstate pelvic radiation within the past 12 months\nSignificant cardiac impairment\nCurrent alcohol or chemical abuse, or mental or psychiatric condition precluding protocol compliance\nPregnant or nursing\nAllergy to soy, egg, or peanut products\nReceiving another investigational agent (30 day wash-out required prior to first dose)\nNeo-adjuvant therapy prior to baseline staging procedures for the current occurrence of non-muscle invasive bladder cancer\nPrior treatment with a cancer vaccine for this indication\nPrior vaccination with BCG for tuberculosis disease\nPrior splenectomy",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Gary Steinberg, MD",
            "OverallOfficialAffiliation": "University of Chicago",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University of California at Los Angeles",
            "LocationCity": "Los Angeles",
            "LocationState": "California",
            "LocationZip": "90095",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Skyline Urology",
            "LocationCity": "Sherman Oaks",
            "LocationState": "California",
            "LocationZip": "91411",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Skyline Urology",
            "LocationCity": "Torrance",
            "LocationState": "California",
            "LocationZip": "90505",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Urology Center of Colorado",
            "LocationCity": "Denver",
            "LocationState": "Colorado",
            "LocationZip": "80211",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Chicago",
            "LocationCity": "Chicago",
            "LocationState": "Illinois",
            "LocationZip": "60637",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "First Urology",
            "LocationCity": "Jeffersonville",
            "LocationState": "Indiana",
            "LocationZip": "47130",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Horizon Oncology Research",
            "LocationCity": "Lafayette",
            "LocationState": "Indiana",
            "LocationZip": "47905",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Kansas Cancer Center",
            "LocationCity": "Westwood",
            "LocationState": "Kansas",
            "LocationZip": "66205",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Johns Hopkins University",
            "LocationCity": "Baltimore",
            "LocationState": "Maryland",
            "LocationZip": "21287",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Massachusetts",
            "LocationCity": "Worcester",
            "LocationState": "Massachusetts",
            "LocationZip": "01655",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Minnesota",
            "LocationCity": "Minneapolis",
            "LocationState": "Minnesota",
            "LocationZip": "55455",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Washington University School of Medicine",
            "LocationCity": "Saint Louis",
            "LocationState": "Missouri",
            "LocationZip": "63110",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Montefiore Medical Center",
            "LocationCity": "Bronx",
            "LocationState": "New York",
            "LocationZip": "10471",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of North Carolina Chapel Hill",
            "LocationCity": "Chapel Hill",
            "LocationState": "North Carolina",
            "LocationZip": "27599",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Thomas Jefferson University",
            "LocationCity": "Philadelphia",
            "LocationState": "Pennsylvania",
            "LocationZip": "19107",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Carolina Urologic Research Center",
            "LocationCity": "Myrtle Beach",
            "LocationState": "South Carolina",
            "LocationZip": "29572",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Urology of North Texas",
            "LocationCity": "Dallas",
            "LocationState": "Texas",
            "LocationZip": "75231",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "MD Anderson Cancer Center",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77030",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Urology of Virginia",
            "LocationCity": "Virginia Beach",
            "LocationState": "Virginia",
            "LocationZip": "23462",
            "LocationCountry": "United States"
          }
        ]
      }
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Phase I: HS-410 Low Dose",
            "FlowGroupDescription": "In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
          },
          {
            "FlowGroupId": "FG001",
            "FlowGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
            "FlowGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
          },
          {
            "FlowGroupId": "FG002",
            "FlowGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
            "FlowGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
          },
          {
            "FlowGroupId": "FG003",
            "FlowGroupTitle": "Phase II: Placebo Plus BCG",
            "FlowGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
          },
          {
            "FlowGroupId": "FG004",
            "FlowGroupTitle": "Phase II: High-Dose HS-410",
            "FlowGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Overall Study",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "10"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "26"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "26"
                      },
                      {
                        "FlowAchievementGroupId": "FG003",
                        "FlowAchievementNumSubjects": "26"
                      },
                      {
                        "FlowAchievementGroupId": "FG004",
                        "FlowAchievementNumSubjects": "16"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "10"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "17"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "16"
                      },
                      {
                        "FlowAchievementGroupId": "FG003",
                        "FlowAchievementNumSubjects": "23"
                      },
                      {
                        "FlowAchievementGroupId": "FG004",
                        "FlowAchievementNumSubjects": "3"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "0"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "9"
                      },
                      {
                        "FlowAchievementGroupId": "FG002",
                        "FlowAchievementNumSubjects": "10"
                      },
                      {
                        "FlowAchievementGroupId": "FG003",
                        "FlowAchievementNumSubjects": "3"
                      },
                      {
                        "FlowAchievementGroupId": "FG004",
                        "FlowAchievementNumSubjects": "13"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Phase I: HS-410 Low Dose",
            "BaselineGroupDescription": "In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
          },
          {
            "BaselineGroupId": "BG001",
            "BaselineGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
            "BaselineGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
          },
          {
            "BaselineGroupId": "BG002",
            "BaselineGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
            "BaselineGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
          },
          {
            "BaselineGroupId": "BG003",
            "BaselineGroupTitle": "Phase II: Placebo Plus BCG",
            "BaselineGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
          },
          {
            "BaselineGroupId": "BG004",
            "BaselineGroupTitle": "Phase II: High-Dose HS-410",
            "BaselineGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
          },
          {
            "BaselineGroupId": "BG005",
            "BaselineGroupTitle": "Total",
            "BaselineGroupDescription": "Total of all reporting groups"
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "10"
                },
                {
                  "BaselineDenomCountGroupId": "BG001",
                  "BaselineDenomCountValue": "26"
                },
                {
                  "BaselineDenomCountGroupId": "BG002",
                  "BaselineDenomCountValue": "26"
                },
                {
                  "BaselineDenomCountGroupId": "BG003",
                  "BaselineDenomCountValue": "26"
                },
                {
                  "BaselineDenomCountGroupId": "BG004",
                  "BaselineDenomCountValue": "16"
                },
                {
                  "BaselineDenomCountGroupId": "BG005",
                  "BaselineDenomCountValue": "104"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Categorical",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "<=18 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Between 18 and 65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "7"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "12"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "6"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "27"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": ">=65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "9"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "19"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "14"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "20"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "15"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "77"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Age, Continuous",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "years",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "73.2",
                              "BaselineMeasurementSpread": "7.495"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "70.5",
                              "BaselineMeasurementSpread": "11.176"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "68.58",
                              "BaselineMeasurementSpread": "11.518"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "70.58",
                              "BaselineMeasurementSpread": "9.047"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "72.50",
                              "BaselineMeasurementSpread": "9.784"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "70.60",
                              "BaselineMeasurementSpread": "10.172"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "6"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "18"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "9"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "23"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "21"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "20"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "13"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "86"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "5"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Not Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "10"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "25"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "24"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "24"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "16"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "99"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Race (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "American Indian or Alaska Native",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Asian",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Black or African American",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "2"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "White",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "10"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "26"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "25"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "23"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "16"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "100"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "More than one race",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Region of Enrollment",
            "BaselineMeasureParamType": "Number",
            "BaselineMeasureUnitOfMeasure": "participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassTitle": "United States",
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "10"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "26"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "26"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG003",
                              "BaselineMeasurementValue": "26"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG004",
                              "BaselineMeasurementValue": "16"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG005",
                              "BaselineMeasurementValue": "104"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Phase 1: Safety and Tolerability",
            "OutcomeMeasureDescription": "To evaluate the safety and tolerability of vesigenurtacel-L",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 3 years.",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase I: HS-410 Low Dose",
                  "OutcomeGroupDescription": "HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections."
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "10"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "Gastrointestinal Disorders",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "General Disorders & Administration Site Conditions",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "5"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Musculoskeletal & Connective Tissue Disorders",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Phase 2: 1-year Disease-Free Survival",
            "OutcomeMeasureDescription": "Arm 1, 2, 3: 1-year DFS in patients with NMIBC treated with BCG in combination with blinded study product (one of two doses of vesigenurtacel-L or placebo) Arm 4: 1-year DFS in patients with NMIBC treat1fv 9 with high dose vesigenurtacel-L monotherapy\n\nOne-year disease-free survival will be defined as the proportion of patients who are free from recurrent disease, progressive disease, and alive one year after the date of randomization/treatment assignment",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "One year",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "7"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "9"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "6"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "12"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Proportion of Patients With Recurrence at 3, 6, 12, 18, and 24 Months",
            "OutcomeMeasureDescription": "Evaluate the proportion of patients with recurrence at 3, 6, 12, 18, and 24 months",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "3 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "22"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "19"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "23"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "14"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "6 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "19"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "19"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "22"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "9"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "12 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "18"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "17"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "21"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "18 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "18"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "16"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "15"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "24 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "14"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "14"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "12"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Proportion of Patients With Progressive Disease at 3, 6, 12, 18, and 24 Months",
            "OutcomeMeasureDescription": "Evaluate the proportion of patients with progressive disease at 3, 6, 12, 18, and 24",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "3 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "6 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "12 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "18 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "24 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "3"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "2"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Disease-free Survival at 3, 6, 18, and 24 Months",
            "OutcomeMeasureDescription": "Evaluate Disease Free Survival at 3, 6, 18 and 24 months",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "3 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "22"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "19"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "23"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "14"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "6 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "19"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "19"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "22"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "9"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "12 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "18"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "17"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "21"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "18 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "17"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "16"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "15"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "24 months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "13"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "14"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "12"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Overall Disease-free Survival",
            "OutcomeMeasureDescription": "Evaluate overall Disease Free Survival",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "18"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "17"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "18"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "3"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Overall Survival, Expressed as the Number of Participants Alive",
            "OutcomeMeasureDescription": "Evaluate overall survival (OS)",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "26"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "26"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "26"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "16"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Proportion of Patients Undergoing Repeat Transurethral Resection of Bladder Tumor (TURBT) by 12 and 24 Months",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "12 Month",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "6"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "10"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "24 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "7"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "11"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Proportion of Patients Undergoing Cystectomy by 12 and 24 Months",
            "OutcomeMeasureDescription": "Evaluate the proportion of patients undergoing cystectomy by 12 and 24 months from randomization",
            "OutcomeMeasurePopulationDescription": "Phase I is not applicable since the Outcome Measure is solely for Phase II; as pre-specified, only Phase II data would be collected.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Number",
            "OutcomeMeasureUnitOfMeasure": "participants",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "26"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "16"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "12 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "24 Months",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "1"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG002",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG003",
                              "OutcomeMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Immunologic Response of PBMCs Via Intracellular Cytokine Staining (ICS) by Flow Cytometry and/or Enzyme-linked Immunosorbent Spot (ELISPOT) on CD8+ Cells After HS-410 Vaccination as Compared to Baseline.",
            "OutcomeMeasureDescription": "Evaluate the proportion of patients with immunologic response of peripheral blood mononuclear cells (PBMCs) via intracellular cytokine staining (ICS) by flow cytometry and/or ELISPOT on CD8+ cells following vesigenurtacel-L vaccination",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 10 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Immunologic Response of Peripheral Blood Mononuclear Cells (PBMCs) and Stimulation Analysis Via ICS in Baseline and Post-treatment Biopsies, if Clinically Indicated",
            "OutcomeMeasureDescription": "Evaluate immunologic response of PBMCs (analysis of surface markers, CD3, CD4, CD8, CD19, CD25, CD45, CD56, FoxP3, and degranulation) and stimulation analysis via ICS of interferon gamma (IFNŒ≥) and granzyme B (gzB)",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 11 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Total PBMC Counts by Flow Cytometry",
            "OutcomeMeasureDescription": "Evaluate total PBMC counts by flow cytometry, including lymphocyte subsets (B cells, helper T-cells, cytotoxic T-cells, natural killer (NK) cells and T-reg)",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 12 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Tumor Antigen Expression",
            "OutcomeMeasureDescription": "Evaluation of pre-treatment tumor tissue for antigen expression",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 13 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "At screening",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Tumor Infiltrating Lymphocytes (TILs)",
            "OutcomeMeasureDescription": "Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 14 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "T Cell Receptor Sequencing of Peripheral Blood T Cells Before and During Treatment",
            "OutcomeMeasureDescription": "Evaluation of tumor tissue obtained from repeat biopsy, if clinically indicated, for presence of TILs, T cell receptor sequencing of peripheral blood T cells before and during the course of treatment.",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 15 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 2 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Safety of the Combination of the HS-410 and BCG",
            "OutcomeMeasureDescription": "Phase 2 only Evaluate the safety of the combination of vesigenurtacel-L and BCG",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 16 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 1 year",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Safety of the High Dose HS-410 Monotherapy",
            "OutcomeMeasureDescription": "Phase 2 only Evaluate the safety of high dose vesigenurtacel-L monotherapy",
            "OutcomeMeasurePopulationDescription": "Data were not collected as pre-specified in Outcome Measure 17 due to study termination by the Sponsor.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years.",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG002",
                  "OutcomeGroupTitle": "Phase II: Placebo Plus BCG",
                  "OutcomeGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium"
                },
                {
                  "OutcomeGroupId": "OG003",
                  "OutcomeGroupTitle": "Phase II: High-Dose HS-410",
                  "OutcomeGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG002",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG003",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "5",
      "EventsTimeFrame": "AEs were defined as all reported events with a start date on or after Study Day 1. All AEs were collected through 30 days post last dose, up to 3 years.",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Phase I: HS-410 Low Dose",
            "EventGroupDescription": "In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "10",
            "EventGroupSeriousNumAffected": "0",
            "EventGroupSeriousNumAtRisk": "10",
            "EventGroupOtherNumAffected": "7",
            "EventGroupOtherNumAtRisk": "10"
          },
          {
            "EventGroupId": "EG001",
            "EventGroupTitle": "Phase II: HS-410 Low-Dose Plus BCG",
            "EventGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "26",
            "EventGroupSeriousNumAffected": "8",
            "EventGroupSeriousNumAtRisk": "26",
            "EventGroupOtherNumAffected": "24",
            "EventGroupOtherNumAtRisk": "26"
          },
          {
            "EventGroupId": "EG002",
            "EventGroupTitle": "Phase II: High-Dose HS-410 Plus BCG",
            "EventGroupDescription": "In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96\n\nBCG: Vaccine derived from a live bacterium",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "26",
            "EventGroupSeriousNumAffected": "4",
            "EventGroupSeriousNumAtRisk": "26",
            "EventGroupOtherNumAffected": "19",
            "EventGroupOtherNumAtRisk": "26"
          },
          {
            "EventGroupId": "EG003",
            "EventGroupTitle": "Phase II: Placebo Plus BCG",
            "EventGroupDescription": "In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.\n\nPlacebo: Injection containing sterile solution but no cells\n\nBCG: Vaccine derived from a live bacterium",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "26",
            "EventGroupSeriousNumAffected": "1",
            "EventGroupSeriousNumAtRisk": "26",
            "EventGroupOtherNumAffected": "20",
            "EventGroupOtherNumAtRisk": "26"
          },
          {
            "EventGroupId": "EG004",
            "EventGroupTitle": "Phase II: High-Dose HS-410",
            "EventGroupDescription": "In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.\n\nHS-410: Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "16",
            "EventGroupSeriousNumAffected": "2",
            "EventGroupSeriousNumAtRisk": "16",
            "EventGroupOtherNumAffected": "9",
            "EventGroupOtherNumAtRisk": "16"
          }
        ]
      },
      "SeriousEventList": {
        "SeriousEvent": [
          {
            "SeriousEventTerm": "Cystoprostatectomy",
            "SeriousEventOrganSystem": "Renal and urinary disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Hypoxia",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Prostate Cancer",
            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Urinary Tract Infection",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pyrexia",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Aneurysm",
            "SeriousEventOrganSystem": "Vascular disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "Mycotic Aneurysm; Disseminated BCG Mycotic Aneurysm",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Transient Ischaemic Attack",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Mental Status Changes",
            "SeriousEventOrganSystem": "Psychiatric disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Anaemia",
            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Haematoma",
            "SeriousEventOrganSystem": "Vascular disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Sepsis",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Squamous Cell Carcinoma",
            "SeriousEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventNotes": "of Larynx",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cerebrovascular Accident",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Rectal Haemorrhage",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cardiac Failure Congestive",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Atrial Fibrillation",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Priapism",
            "SeriousEventOrganSystem": "Reproductive system and breast disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Disease Progression",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Urinary Retention",
            "SeriousEventOrganSystem": "Renal and urinary disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Bladder Perforation",
            "SeriousEventOrganSystem": "Renal and urinary disorders",
            "SeriousEventSourceVocabulary": "medDRA v20.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "10"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG002",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG003",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "26"
                },
                {
                  "SeriousEventStatsGroupId": "EG004",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "16"
                }
              ]
            }
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Anemia",
            "OtherEventOrganSystem": "Blood and lymphatic system disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vertigo",
            "OtherEventOrganSystem": "Ear and labyrinth disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dry Eye",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vision Blurred",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Constipation",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Diarrhoea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dry Mouth",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nausea",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Vomiting",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Asthenia",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Chills",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Fatigue",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "14",
                  "OtherEventStatsNumAffected": "10",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "11",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Influenza Like Illness",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Malaise",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pain",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pyrexia",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cystitis",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Folliculitis",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Herpes Zoster",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nasopharyngitis",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pharyngitis Streptococcal",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Upper Respiratory Tract Infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary Tract Infection",
            "OtherEventOrganSystem": "Infections and infestations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "8",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "7",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blood Urine Present",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hematocrit Decreased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "White Blood Cell Count Increased",
            "OtherEventOrganSystem": "Investigations",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Decreased Appetite",
            "OtherEventOrganSystem": "Metabolism and nutrition disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Arthralgia",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Back Pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Musculoskeletal Pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Myalgia",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pain in Extremity",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cerebrovascular Disorder",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dizziness",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Headache",
            "OtherEventOrganSystem": "Nervous system disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Insomnia",
            "OtherEventOrganSystem": "Psychiatric disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bladder Perforation",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bladder Spasm",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dysuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "10",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "18",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "11",
                  "OtherEventStatsNumAffected": "9",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Haematuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "9",
                  "OtherEventStatsNumAffected": "6",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "13",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Lower Urinary Tract Symptoms",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Micturition Urgency",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "19",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pollakiuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "6",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "18",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary Incontinence",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary Retention",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Breast Tenderness",
            "OtherEventOrganSystem": "Reproductive system and breast disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Cough",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Oropharyngeal Pain",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Upper Airway Cough Syndrome",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eczema",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pruritis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urticaria",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hypertension",
            "OtherEventOrganSystem": "Vascular disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Injection Site Pain",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "4",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Injection Site Erythema",
            "OtherEventOrganSystem": "General disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hyperadrenalism",
            "OtherEventOrganSystem": "Endocrine disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eye Haemorrhage",
            "OtherEventOrganSystem": "Eye disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dental Caries",
            "OtherEventOrganSystem": "Gastrointestinal disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Flank Pain",
            "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Bladder Spasm",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nephrolithiasis",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nephropathy",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pollakiuria",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Urinary Retention",
            "OtherEventOrganSystem": "Renal and urinary disorders",
            "OtherEventSourceVocabulary": "medDRA v20.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "10"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG002",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG003",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "26"
                },
                {
                  "OtherEventStatsGroupId": "EG004",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "16"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "No",
        "AgreementRestrictiveAgreement": "No"
      },
      "PointOfContact": {
        "PointOfContactTitle": "Lori McDermott",
        "PointOfContactOrganization": "Clinical Development",
        "PointOfContactEMail": "lmcdermott@heatbio.com",
        "PointOfContactPhone": "9197948950",
        "PointOfContactPhoneExt": "9197948950"
      }
    }
  },
  "DocumentSection": {
    "LargeDocumentModule": {
      "LargeDocList": {
        "LargeDoc": [
          {
            "LargeDocTypeAbbrev": "Prot",
            "LargeDocHasProtocol": "Yes",
            "LargeDocHasSAP": "No",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Study Protocol",
            "LargeDocDate": "February 3, 2016",
            "LargeDocUploadDate": "06/27/2019 12:55",
            "LargeDocFilename": "Prot_000.pdf"
          },
          {
            "LargeDocTypeAbbrev": "SAP",
            "LargeDocHasProtocol": "No",
            "LargeDocHasSAP": "Yes",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Statistical Analysis Plan",
            "LargeDocDate": "October 19, 2016",
            "LargeDocUploadDate": "06/27/2019 12:56",
            "LargeDocFilename": "SAP_001.pdf"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001749",
            "ConditionMeshTerm": "Urinary Bladder Neoplasms"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000014571",
            "ConditionAncestorTerm": "Urologic Neoplasms"
          },
          {
            "ConditionAncestorId": "D000014565",
            "ConditionAncestorTerm": "Urogenital Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000001745",
            "ConditionAncestorTerm": "Urinary Bladder Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4182",
            "ConditionBrowseLeafName": "Urinary Bladder Neoplasms",
            "ConditionBrowseLeafAsFound": "Bladder Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16472",
            "ConditionBrowseLeafName": "Urologic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16467",
            "ConditionBrowseLeafName": "Urogenital Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4178",
            "ConditionBrowseLeafName": "Urinary Bladder Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000001500",
            "InterventionMeshTerm": "BCG Vaccine"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000276",
            "InterventionAncestorTerm": "Adjuvants, Immunologic"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M16512",
            "InterventionBrowseLeafName": "Vaccines",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M21013",
            "InterventionBrowseLeafName": "Pharmaceutical Solutions",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3945",
            "InterventionBrowseLeafName": "BCG Vaccine",
            "InterventionBrowseLeafAsFound": "Collar",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M2780",
            "InterventionBrowseLeafName": "Adjuvants, Immunologic",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "PhSol",
            "InterventionBrowseBranchName": "Pharmaceutical Solutions"
          }
        ]
      }
    }
  }
}